文献速递心脏核医学放射性药物与辐射防护

99mTc标记岩藻聚糖靶向P-选择素的SPECT示踪剂首次人体研究

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin.
PubMed 文献 · EJNMMI Res · 2024-11-19

在10名健康志愿者中评估99mTc-岩藻聚糖的安全性、全身生物分布与剂量学,并检测其与体外及体内人血栓的结合。该示踪剂耐受良好,离体血栓结合可被Sialyl Lewis X部分阻断,但3例深静脉血栓患者中仅1例见血栓部位特异性摄取。

要点

  • 99mTc-岩藻聚糖在健康志愿者中耐受良好,未见药物相关不良事件。
  • 男性全身吸收剂量与女性相当(0.012 ± 0.004 vs 0.011 ± 0.005 mSv/MBq,p=0.97)。
  • 体内结果不支持进一步临床研究99mTc-岩藻聚糖作为深静脉血栓的显像手段。

核心结论

  • 99mTc-岩藻聚糖生物分布良好且安全性好,在体内和体外均显示与人类血栓特异性结合。
  • 体内结果不支持进一步临床研究99mTc-岩藻聚糖作为深静脉血栓的显像模态,应考虑99mTc标记P-选择素示踪剂的其他临床应用。

研究设计与样本

  • 首次人体研究,在10名健康志愿者中评估99mTc-岩藻聚糖的安全性、全身生物分布与剂量学。
  • 健康志愿者静脉注射99mTc-岩藻聚糖370 MBq后行全身扫描至24小时。
  • 用γ计数法测量99mTc-岩藻聚糖在离体人血栓(n=11)中的摄取。
  • 对3例新诊断深静脉血栓患者行99mTc-岩藻聚糖SPECT/CT显像。

主要发现

  • 99mTc-岩藻聚糖在所有参与者中耐受良好,无药物相关不良事件。
  • 男性全身吸收剂量与女性相当(0.012 ± 0.004 vs 0.011 ± 0.005 mSv/MBq;p=0.97)。
  • γ计数显示示踪剂与离体人血栓结合,经天然P-选择素配体Sialyl Lewis X阻断后结合降低16%。
  • 3例接受扫描的深静脉血栓患者中,1例在血栓部位显示99mTc-岩藻聚糖特异性摄取。

临床怎么用

  • 作者结论认为体内结果不支持进一步临床研究99mTc-岩藻聚糖作为深静脉血栓的显像模态。
  • 作者提出应考虑99mTc标记P-选择素示踪剂的其他临床应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of 99mTc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of 99mTc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of 99mTc-fucoidan (370 MBq). Moreover, 99mTc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to 99mTc-fucoidan SPECT/CT imaging. RESULTS: 99mTc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq; p = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X. 99mTc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT. CONCLUSIONS: 99mTc-Fucoidan has a favorable biodistribution and safety profile. 99mTc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of 99mTc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium- 99m-labeled P-selectin tracer should be considered. TRIAL REGISTRATION: Clinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739. Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Oostveen RF, Zheng KH, Kaiser Y, et al. First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin. EJNMMI Res. 2024. PMID: 39562382. doi:10.1186/s13550-024-01173-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。